Subscribe to Updates in Healthcare

RSS By Email

RSS By RSS

Add to Google Reader or Homepage

Subscribe in Bloglines


The Expertise Imperative and Compliance Technology
Access to a diverse array of specialized expert inputs drives superior decisions in every organizational context: within corporations, by investors and consultancies, and within nonprofits. When decision makers are confident of their decision inputs, they can respond more quickly and creatively to challenges and opportunities.Learn more about GLG's Compliance Framework


This page may include content provided by Council Members, your access to which is subject to the Terms of Use.
Find Out More

GLG News by Effexor XR Prescribers (US)

Articles with lock require a subscription to GLG News | Request a free trial
November 24, 2008
Efficacy isn't everything
Analysis of: 2nd Generation Antidepressants Prove Effective | health.usnews.com
Author: GLG Expert Contributor
This article tells you only that the drugs are equally effective, but not what that really means in real life.
Louis SanfilippoNovember 10, 2008
Astra Zeneca Seeking to Widen Indications, Markets for Seroquel XR
Analysis of: AstraZeneca Announces European SEROQUEL XR Submission for the Treatment of Generalised Anxiety Disorder | www.pharmalive.com
Author: Louis Sanfilippo, President, LCS Group, LLC
Astra Zeneca is pursuing important medical and, of course, commercial goals by seeking the expanded clinical indications of major depression and generalized anxiety disorder for Seroquel XR, heir to blockbuster Seroquel (quetiapine).  This latest EU submission culminates regulatory submissions...
October 13, 2008
Just because they say so, it ain't necessarily so.....
Analysis of: St John's Wort 'as good as Prozac' | ukpress.google.com
Author: GLG Expert Contributor
This "report" tells you nothing that you need to know in order to assess the validity of these studies.  We have always known that St. John's Wort has some effectiveness---but it certainly does not come without side-effects.  Where is the information about the length of the studies, the relative...
October 8, 2008
Interesting, but be cautious
Analysis of: Lilly Announces Initiation of Second Global Phase III Trial of Investigational Alzheimer's Disease Compound | newsroom.lilly.com
Author: GLG Expert Contributor
Gamma secretase inhibitors are one of several kinds of drugs being studied for the prevention/amelioration of Alzheimer's.  In concept they make sense.
September 11, 2008
Psychotherapy may save money
Analysis of: National Trends in Psychotherapy by Office-Based Psychiatrists | archpsyc.ama-assn.org
Author: GLG Expert Contributor
Unfortunately, many insurance payors do not realize that allowing psychotherapy visits may save the money in the long run by reducing the need for much more costly Inpatient psychiatric treatment. I find that my patients who receive psychotherapy are much less likely to miss work and much...
September 1, 2008
The Devil Is in the Details
Analysis of: ADAGIO Trial Results Show Teva's AZILECT(R) 1 Mg Tablets Slow Progression Of Parkinson's Disease | www.medicalnewstoday.com
Author: GLG Expert Contributor
This large study shows that PD patients' severity of motor dysfunction is better on rasagiline than on placebo.
July 31, 2008
Be very careful
Analysis of: Blood pressure drugs may protect against Alzheimer's | www.washingtonpost.com
Author: GLG Expert Contributor
All is not as it seems when reported in the press, especially the non-scientific press.
July 28, 2008
Pharmacogenetic Tests for Antidepressants Disappointing So Far
Analysis of: TheraGenetics Licenses Intellectual Property Related To Predicting Patient Response To Antidepressant Therapy | www.medicalnewstoday.com
Author: GLG Expert Contributor
-Pharmacogenetic tests have not made it into the treatment or assessment process for most physicians. -Until the cost for these tests become negligible -- or, included in the cost of a particular antidepressant -- psychopharmacogenetic testing will not make it into the mainstream. 
Louis SanfilippoJuly 21, 2008
A Small Company, A Big Idea
Analysis of: TheraGenetics Licenses Intellectual Property Related To Predicting Patient Response To Antidepressant Therapy | www.medicalnewstoday.com
Author: Louis Sanfilippo, President, LCS Group, LLC
“Personalized medical diagnositics” looks to be evolving as a high impact area in neuropsychiatric drug development.  Such ‘genetic biomarker’ platforms, based on either pharmacogenetic profiles coming from DNA blueprints or gene products from a simple blood draw, aim to identify patients who are...
Louis SanfilippoJuly 3, 2008
One Drug, Many Uses -- Mostly a Very Good Idea
Analysis of: One drug, many uses. Good idea? | www.indystar.com
Author: Louis Sanfilippo, President, LCS Group, LLC
‘One drug, many uses’ can make lots of sense clinically and commercially.   Seeking additional FDA indications for a specific drug has obvious business benefits:  greater revenue stream, improved branding, potentially longer market exclusivity, greater franchising potential of the drug...

Page : 1 2 3 4 5 6 7 8 9 10 Next1 to 10 of 408

More GLG News in
Healthcare

Most Popular:
Source Article | Expert Analyses
 

GLG News: What Experts Think Is Important





Analytics


Generated at 2008-12-02T13:45:17.613